> the lack of real-world efficacy stems from the difficulty in adhering to the treatment

Do you have a source for this "lack of real-world efficacy"?

> This study found that 84.4% non-diabetic patients stop taking GLP-1 drugs within two years

"With a with a median on-treatment weight change of −2.9%" [1]. Of those who discontinued and experienced "weight gain since discontinuation," they were "associated with an increased likelihood of GLP-1 RA reinitiation."

I'm genuinely struggling to see how this source shows real world inefficacy. In my friends, all of them stopped taking GLP-1 drugs within 2 years because all of them lost the weight they wanted to.

Out of curiosity, what sources lead you to believe this?

> it's like the drug disulfiram

Have clinicians made this connection?

[1] https://jamanetwork.com/journals/jamanetworkopen/fullarticle...